EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Impact of conventional lipid‐lowering therapy on circulating levels of p roprotein convertase subtilisin/kexin type 9: A systematic review and meta‐analysis of randomised controlled trials

Lingyan Meng, Tianze Huang, Shuaiwei Guo, Tao Wang, Ran Xu, Xue Wang, Long Li, Yifan Yang, Renjie Yang, Jie Wang, Hai Yang, Yan Ma und 3 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70475 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Lingyan Meng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Hypolipidemic Agents, Dyslipidemias. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Beijing Natural Science Foundation-Daxing Joint Fund Project, Young Scientists Fund of the National Natural Science Foundation of China, Nocommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional lipid‐lowering agents, such as statins, ezetimibe, fibrates, bile acid sequestrants, nicotinic acid, bempedoic acid, and omega‐3, play a pivotal role in managing dyslipidemia. Despite their benefits, these agents are associated with increased levels of plasma proprotein convertase subtilisin kexin 9 (PCSK9), a serine protease linked to elevated cardiovascular risk. The literature lacks comprehensive data on how these commonly used drugs collectively impact circulating PCSK9 levels alongside their lipid‐modifying effects. This review addresses this gap by systematically analysing the effects of these agents on PCSK9 and lipid profiles. Following the preferred reporting items for systematic review and meta‐analysis protocols guidelines, this study conducts a systematic search across multiple databases including MEDLINE, Cochrane Central, EMBASE, Web of Science, SCOPUS, and ScienceDirect. We include published, peer‐reviewed randomised controlled trials (RCTs) that involve adult patients undergoing monotherapy or combination therapy with the mentioned lipid‐lowering drugs for at least 2 weeks, with recorded PCSK9 levels at baseline and post‐treatment. Our analysis encompasses data extraction and bias assessment independently performed by two researchers, utilising standardised mean difference for continuous data and risk ratios for dichotomous data. We also conduct subgroup and sensitivity analyses to assess treatment intensity, drug types, comorbidities, and geographical variations in study outcomes. Publication bias is evaluated through funnel plot and Egger's test. The meta‐analysis includes 14 RCTs with 21 treatment arms, involving 1313 participants. Results indicate a significant increase in plasma PCSK9 levels following treatment with conventional lipid‐lowering drugs (weighted mean difference: 23.25 ng/mL; 95% confidence interval: 17.00, 29.50; p < 0.01; I 2 = 56%). Notably, subgroup analyses reveal significant differences based on treatment intensity, type of lipid‐lowering agent, underlying diseases, and trial location. This systematic review confirms that conventional lipid‐lowering drugs significantly elevate plasma PCSK9 levels. These findings highlight the necessity for clinicians to monitor PCSK9 concentrations in patients undergoing lipid‐lowering treatment to optimise therapeutic strategies and mitigate associated cardiovascular risks. Our study contributes to a nuanced understanding of the biochemical effects of lipid‐lowering therapies, potentially guiding future clinical practices and research in cardiovascular risk management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Hypolipidemic AgentsDyslipidemiasHumansRandomized Controlled Trials as TopicCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsFibric AcidsNiacinEzetimibeFatty Acids, Omega-3

Stichwörter der Autor:innen

PCSK9cardiovascular diseaselipid‐lowing therapymeta‐analysis

Substanzen

Proprotein Convertase 9PCSK9 protein, humanHypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsFibric AcidsNiacinEzetimibeFatty Acids, Omega-3

Autor:innen und Institutionen

  • Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • China International Neuroscience Institute (China-INI), Beijing, Beijing, China.
  • Peking Union Medical College, Beijing, China.
  • Medical Library, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of Neurology, Datong Third People's Hospital, Datong, Shanxi, China.
  • Department of Interventional Radiology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Förderung

  • Beijing Natural Science Foundation-Daxing Joint Fund Project
  • Young Scientists Fund of the National Natural Science Foundation of China
  • Nocommunicable Chronic Diseases-National Science and Technology Major Project
  • Natural Science Foundation for Young Scientists of Shanxi Province

Zitieren

APA

Meng, L., Huang, T., Guo, S., Wang, T., Xu, R., Wang, X., Li, L., Yang, Y., Yang, R., Wang, J., Yang, H., Ma, Y., Yang, B., Luo, J., & Jiao, L. (2026). Impact of conventional lipid‐lowering therapy on circulating levels of p roprotein convertase subtilisin/kexin type 9: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70475

Vancouver

Meng L, Huang T, Guo S, Wang T, Xu R, Wang X, et al. Impact of conventional lipid‐lowering therapy on circulating levels of p roprotein convertase subtilisin/kexin type 9: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70475

BibTeX
@article{Meng2026,
  author = {Meng, Lingyan and Huang, Tianze and Guo, Shuaiwei and Wang, Tao and Xu, Ran and Wang, Xue and Li, Long and Yang, Yifan and Yang, Renjie and Wang, Jie and Yang, Hai and Ma, Yan and Yang, Bin and Luo, Jichang and Jiao, Liqun},
  title = {Impact of conventional lipid‐lowering therapy on circulating levels of p roprotein convertase subtilisin/kexin type 9: A systematic review and meta‐analysis of randomised controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70475}
}
Kostenlos starten →